FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2313348550> ?p ?o ?g. }

• W2313348550 abstract "Integrins are cell-surface adhesion proteins that interact with various components of the extracellular matrix and play an important role in intracellular signaling, cell adhesion, migration, and proliferation. The expression of α V integrins has been associated with poor clinical outcome in patients with non-small cell lung cancer (NSCLC). Intetumumab (CNTO 95) is a novel, fully human monoclonal antibody against all members of the α V integrin family including α V β1, α V β3, α V β5, α V β6, and α V β8. Intetumumab inhibits cell adhesion, migration, proliferation, and induces apoptosis in tumor and endothelial cells in vitro. Intetumumab inhibits tumor growth, metastasis, and angiogenesis in vivo in rat xenograft models. Here, we describe experiments to understand the mechanism of action of intetumumab in NSCLC models in vitro and in vivo. The focal adhesion complex and α V integrins play crucial roles in adhesion, motility, and migration in both normal and cancer cells. NSCLC cells were cultured on a vitronectin matrix to stimulate signaling through the α V integrin pathway and then treated with intetumumab (10 µg/ml). Intetumumab treatment resulted in the reduction of phosphorylated FAK (Y397) and Paxillin (Y31) compared to controls up through 48 hours. FAK has been shown to participate in downstream processes such as cell cycle progression by modulating ERK1/2, AKT and the cyclin-dependent kinase inhibitor p27 KIP1 . Intetumumab treatment of NSCLC cell lines in vitro resulted in the reduction of phosphorylated ERK1/2 and AKT and the subsequent upregulation of p27 KIP1 . Furthermore, intetumumab treatment activated the intrinsic pathway of apoptosis as evidenced by the cleavage of caspase 9 and PARP as well as increased Bim expression. In vivo administration of intetumumab (10 mg/kg, i.p., 3x weekly) alone or in combination with docetaxel (up to 20 mg/kg, i.p., weekly for 3 weeks) significantly inhibited the growth of established A549 human NSCLC tumor xenografts in nude rats as a monotherapy (p In conclusion, the results presented here demonstrate the impact of intetumumab on the cellular and molecular mechanisms mediating cell survival through the α V integrin signaling pathway resulting in disruption of focal adhesion complexes, inhibition of cell cycle progression at the G1 phase and induction of the cell intrinsic pathway of apoptosis. Taken together these results demonstrate enhanced anti-tumor efficacy in an established NSCLC preclinical model and suggest the potential for clinical evaluation of intetumumab in NSCLC patients. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2334." @default.
• W2313348550 created "2016-06-24" @default.
• W2313348550 creator A5008996818 @default.
• W2313348550 creator A5020130472 @default.
• W2313348550 creator A5022288435 @default.
• W2313348550 creator A5022400508 @default.
• W2313348550 creator A5055073284 @default.
• W2313348550 creator A5060746643 @default.
• W2313348550 creator A5068334806 @default.
• W2313348550 creator A5089019174 @default.
• W2313348550 date "2010-04-15" @default.
• W2313348550 modified "2023-09-27" @default.
• W2313348550 title "Abstract 2334: A novel αVintegrin antibody, intetumumab (CNTO 95), enhances anti-tumor activity against human non-small cell lung cancer through disruption of the FAK/ERK/AKT pathway and regulation of p27KIP1" @default.
• W2313348550 doi "https://doi.org/10.1158/1538-7445.am10-2334" @default.
• W2313348550 hasPublicationYear "2010" @default.
• W2313348550 type Work @default.
• W2313348550 sameAs 2313348550 @default.
• W2313348550 citedByCount "0" @default.
• W2313348550 crossrefType "proceedings-article" @default.
• W2313348550 hasAuthorship W2313348550A5008996818 @default.
• W2313348550 hasAuthorship W2313348550A5020130472 @default.
• W2313348550 hasAuthorship W2313348550A5022288435 @default.
• W2313348550 hasAuthorship W2313348550A5022400508 @default.
• W2313348550 hasAuthorship W2313348550A5055073284 @default.
• W2313348550 hasAuthorship W2313348550A5060746643 @default.
• W2313348550 hasAuthorship W2313348550A5068334806 @default.
• W2313348550 hasAuthorship W2313348550A5089019174 @default.
• W2313348550 hasConcept C116581196 @default.
• W2313348550 hasConcept C137738243 @default.
• W2313348550 hasConcept C1491633281 @default.
• W2313348550 hasConcept C151166631 @default.
• W2313348550 hasConcept C164144092 @default.
• W2313348550 hasConcept C185592680 @default.
• W2313348550 hasConcept C189165786 @default.
• W2313348550 hasConcept C195687474 @default.
• W2313348550 hasConcept C2780394083 @default.
• W2313348550 hasConcept C502942594 @default.
• W2313348550 hasConcept C55493867 @default.
• W2313348550 hasConcept C62112901 @default.
• W2313348550 hasConcept C62478195 @default.
• W2313348550 hasConcept C75217442 @default.
• W2313348550 hasConcept C85789140 @default.
• W2313348550 hasConcept C86492073 @default.
• W2313348550 hasConcept C86554907 @default.
• W2313348550 hasConcept C86803240 @default.
• W2313348550 hasConcept C95444343 @default.
• W2313348550 hasConceptScore W2313348550C116581196 @default.
• W2313348550 hasConceptScore W2313348550C137738243 @default.
• W2313348550 hasConceptScore W2313348550C1491633281 @default.
• W2313348550 hasConceptScore W2313348550C151166631 @default.
• W2313348550 hasConceptScore W2313348550C164144092 @default.
• W2313348550 hasConceptScore W2313348550C185592680 @default.
• W2313348550 hasConceptScore W2313348550C189165786 @default.
• W2313348550 hasConceptScore W2313348550C195687474 @default.
• W2313348550 hasConceptScore W2313348550C2780394083 @default.
• W2313348550 hasConceptScore W2313348550C502942594 @default.
• W2313348550 hasConceptScore W2313348550C55493867 @default.
• W2313348550 hasConceptScore W2313348550C62112901 @default.
• W2313348550 hasConceptScore W2313348550C62478195 @default.
• W2313348550 hasConceptScore W2313348550C75217442 @default.
• W2313348550 hasConceptScore W2313348550C85789140 @default.
• W2313348550 hasConceptScore W2313348550C86492073 @default.
• W2313348550 hasConceptScore W2313348550C86554907 @default.
• W2313348550 hasConceptScore W2313348550C86803240 @default.
• W2313348550 hasConceptScore W2313348550C95444343 @default.
• W2313348550 hasLocation W23133485501 @default.
• W2313348550 hasOpenAccess W2313348550 @default.
• W2313348550 hasPrimaryLocation W23133485501 @default.
• W2313348550 hasRelatedWork W1945555781 @default.
• W2313348550 hasRelatedWork W196646593 @default.
• W2313348550 hasRelatedWork W1978548948 @default.
• W2313348550 hasRelatedWork W1982898420 @default.
• W2313348550 hasRelatedWork W1992103231 @default.
• W2313348550 hasRelatedWork W1992925170 @default.
• W2313348550 hasRelatedWork W2040066617 @default.
• W2313348550 hasRelatedWork W2072491772 @default.
• W2313348550 hasRelatedWork W2077981972 @default.
• W2313348550 hasRelatedWork W2095031931 @default.
• W2313348550 hasRelatedWork W2170974121 @default.
• W2313348550 hasRelatedWork W2464767256 @default.
• W2313348550 hasRelatedWork W2621093096 @default.
• W2313348550 hasRelatedWork W2790370335 @default.
• W2313348550 hasRelatedWork W2795478721 @default.
• W2313348550 hasRelatedWork W2802670193 @default.
• W2313348550 hasRelatedWork W2889680119 @default.
• W2313348550 hasRelatedWork W2908582408 @default.
• W2313348550 hasRelatedWork W2942776715 @default.
• W2313348550 hasRelatedWork W3111888112 @default.
• W2313348550 isParatext "false" @default.
• W2313348550 isRetracted "false" @default.
• W2313348550 magId "2313348550" @default.
• W2313348550 workType "article" @default.